18F-Choline PET/CT, MRI, and Software-Based Image Fusion Analysis in Patients With Primary Hyperparathyroidism

被引:3
|
作者
Hofer, Thomas [1 ,2 ]
Kronbichler, Juergen [1 ,2 ]
Huber, Helmut [1 ,2 ]
Hergan, Benedikt [2 ,3 ]
Kaiser, Bernhard [1 ,2 ]
Shamiyeh, Andreas [2 ,4 ]
Fellner, Franz [2 ,3 ]
Gabriel, Michael [1 ,2 ,5 ]
机构
[1] Kepler Univ Hosp Linz GmbH, Inst Nucl Med & Endocrinol, Krankenhausstr 9, A-4020 Linz, Austria
[2] Johannes Kepler Univ Linz, Med Fac, Linz, Austria
[3] Kepler Univ Hosp Linz GmbH, Cent Radiol Inst, Linz, Austria
[4] Kepler Univ Hosp Linz GmbH, Dept Gen Surg, Linz, Austria
[5] Med Univ Innsbmck, Dept Nucl Med, Innsbruck, Austria
关键词
hyperparathyroidism; F-18-choline PET; CT; MRI; image fusion; multimodality; PARATHYROID ADENOMAS; LOCALIZATION; SCINTIGRAPHY; CT;
D O I
10.1097/RLU.0000000000003738
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of this study was to evaluate the diagnostic performance of F-18-choline PET and MRI in patients with primary hyperparathyroidism. Furthermore, the additional value of software-based PET/MRI scan fusion was analyzed. Patients and Methods This retrospective study includes 42 patients (38 women) with an age between 32.5 and 79.1 years. PET/CT scans were performed on a dedicated system after injection of 250 to 350 MBq F-18-choline. For the MRI examination, T1-weighted images of the cervical region were used. The image fusion was made by anatomical coregistration using an automated algorithm based on mutual information. Results A total of 46 lesions were discovered and histologically confirmed in 42 patients. Histopathological examination revealed 38 adenomas and 8 hyperplasias. This means that, in 4 of these 42 patients, 2 lesions per patient were discovered. PET/CT also detected 46 abnormal findings, but only 43 were correctly recognized, whereas the other 3 were false-positive (FP). Six lesions could not be detected correctly: 3 were FP and 3 false-negative, which resulted in a sensitivity of 93.5% and a specificity of 97.5%. The site-specific evaluation showed 18 true-positive enlarged parathyroid glands with MRI, but also produced 13 FP findings and failed to detect 28 lesions; the sensitivity and specificity are thus 39.1% and 89.3%, respectively. The difference in detection rate between F-18-choline PET/CT and MRI was statistically significant (P < 0.001). Conclusions F-18-choline PET/CT is clearly superior to MRI for localization diagnostics in primary hyperparathyroidism. Image fusion of both modalities can be helpful for more precise anatomical assignment.
引用
收藏
页码:710 / 716
页数:7
相关论文
共 50 条
  • [31] A Thyroid Incidentaloma Detected by 18F-Choline PET/CT
    Treglia, Giorgio
    Giovannini, Elisabetta
    Mirk, Paoletta
    Di Franco, Davide
    Oragano, Luigi
    Bertagna, Francesco
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (04) : E267 - E269
  • [32] Value of 18F-Choline PET-CT in the assessment of primary hyperparathyroidism comparing with 99mTC-Sestamibi SPECT-CT
    Beheshti, M.
    Imamovic, L.
    Spaun, G.
    Steinmair, M.
    Emmanuel, K.
    Alibegovic, V.
    Pirich, C.
    Langsteger, W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S66 - S66
  • [33] 18F-Choline PET/CT Pitfalls in Image Interpretation An Update on 300 Examined Patients With Prostate Cancer
    Calabria, Ferdinando
    Chiaravalloti, Agostino
    Schillaci, Orazio
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (02) : 122 - 130
  • [34] Outcome of PET/CT 18F-Choline in high risk prostate cancer patients
    Lavados, H.
    Pruzzo, R.
    Amaral, H.
    Hernandez, E.
    Morales, B.
    Haeger, A.
    Fernandez, R.
    Hurtado, A.
    Galaz, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S435 - S435
  • [35] 18F-choline PET/MRI in suspected recurrence of prostate carcinoma
    Riola-Parada, C.
    Carreras-Delgado, J. L.
    Perez-Duenas, V
    Garcerant-Tafur, M.
    Garcia-Canamaque, L.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2018, 37 (05): : 296 - 301
  • [36] Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
    Jan D. Soyka
    Marco A. Muster
    Daniel T. Schmid
    Burkhardt Seifert
    Ulrike Schick
    Raymond Miralbell
    Sandra Jorcano
    Kathrin Zaugg
    Hans-Helge Seifert
    Patrick Veit-Haibach
    Klaus Strobel
    Niklaus G. Schaefer
    Daniela B. Husarik
    Thomas F. Hany
    European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39 : 936 - 943
  • [37] Clinical impact of 18F-Choline PET/CT in patients with recurrent prostate carcinoma
    Soyka, Jan
    Muster, Marco
    Schick, Ulrike
    Miralbell, Raymond
    Jorcano, Sandra
    Veit-Haibach, Patrick
    Strobel, Klaus
    Schaefer, Niklaus
    Schmid, Daniel
    Hany, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [38] Appropriateness of prescription of 18F-Choline PET/CT in 218 patients with prostate cancer
    Chondrogiannis, S.
    Marzola, M. C.
    Grassetto, G.
    Borotto, G.
    Tommasi, E.
    Tamiso, L.
    Maffione, A. M.
    Pavan, L.
    Rampin, L.
    Rubello, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S719 - S719
  • [39] Optimizing the acquisition protocol of 18F-Choline PET/CT in prostate cancer patients
    Massaro, Arianna
    Cittadin, Silvia
    Milan, Elisa
    Tamiso, Luca
    Lara, Pavan
    Enrico, Tommasi
    Marzola, Maria Cristina
    Grassetto, Gaia
    Rubello, Domenico
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [40] Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
    Soyka, Jan D.
    Muster, Marco A.
    Schmid, Daniel T.
    Seifert, Burkhardt
    Schick, Ulrike
    Miralbell, Raymond
    Jorcano, Sandra
    Zaugg, Kathrin
    Seifert, Hans-Helge
    Veit-Haibach, Patrick
    Strobel, Klaus
    Schaefer, Niklaus G.
    Husarik, Daniela B.
    Hany, Thomas F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) : 936 - 943